At Incyte, our rigorous pursuit of R&D excellence drives our efforts to create new therapies with the potential to improve the lives of patients, make a difference in healthcare, and build sustainable value for all our stakeholders. We are committed to not only improving the treatment and experience of patients, but also supporting our colleagues, operating our business in a way that protects the environment, and enhancing the communities in which we live and work. We value integrity, as well as ethical and responsible behavior in all aspects of our business, which helps to enable rapid responses to internal and external challenges and opportunities.
A Letter from Hervé
Dear Fellow Stakeholders,
Our science-first approach has been the foundation of our company for almost 20 years, and I am very pleased to report on another year of outstanding achievements at Incyte. During 2020, we announced approvals from the U.S. Food and Drug Administration (FDA) for three new medicines,1 and we navigated the COVID-19 pandemic with agility and resilience. We now have six approved products globally and reported total product and royalty revenues of $2.5 billion, representing an 18% increase over 2019, as well as a strong balance sheet, which illustrates the success of our strategy targeting diversification and growth.
We are also proud of the progress we have made in the five key areas of our Global Responsibility initiative that we established in 2019. Over the last year, we have continued our work to increase our environmental, social and governance (ESG) disclosures and improved upon our objectives. We are proud to share our progress with you.
We recognize that protecting the environment is an important obligation, and we must not wait to take action. For the first time, we have established specific goals that reinforce our commitment to protecting the environment and increasing transparency to our key stakeholders. It is our hope that these goals will help to drive meaningful change to Incyte and to our planet.
We continue to engage with you, our stakeholders, and are pleased to respond to your feedback. My fellow Directors and I would like to thank you for your continued support and encouragement.
1. Pemazyre® (pemigatinib), Tabrecta® (capmatinib) and Monjuvi® (tafasitamab-cxix) were all approved in 2020.
Global Responsibility Contact
To contact the Global Responsibility team, please email us at email@example.com